- Home
- CIK vs BDTX Comparison
CIK vs BDTX Comparison
Compare CIK & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIK | BDTX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 140.7M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CIK | BDTX |
|---|---|---|
| Price | $2.67 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 402.1K | ★ 589.1K |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.45 |
| EPS | N/A | ★ 0.65 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.56 | $1.20 |
| 52 Week High | $3.01 | $4.94 |
Technical Indicators
Market Signals| Indicator | CIK | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.26 | 50.52 |
| Support Level | N/A | $2.42 |
| Resistance Level | $3.00 | $2.67 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 0.00 | 61.76 |
Price Performance
Historical ComparisonAbout CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.